Echo secures $3.6 million for wireless glucose monitor; OctoPlus to aid development of injectable joint treatment;

> Dutch specialty pharmaceutical company OctoPlus says it will begin working with a "leading U.S.-based pharmaceutical company" on a controlled release formulation of a joint treatment using its injectable PolyActive drug delivery technology. Release

> Echo Therapeutics ($ECTE) has raised $3.6 million in cash to help fuel final development of its non-invasive, wireless, transdermal continuous glucose monitoring system for diabetics and critical care patients. Release

> Percutaneous coronary intervention using newer drug-eluting stents to treat blocked arteries has lower rates of relapse, stent thrombosis and death than older drug-eluting and bare-metal stents, an analysis of more than 94,000 consecutive stent implantations in Sweden has found. Release

> U.K. RNAi company Silence Therapeutics will explore combining its DBTC delivery system with miRagen's novel microRNA-based therapeutics. DBTC is a lipid-based formulation that efficiently delivers siRNA to various types of liver cells. Release

> Unigene Laboratories has been granted a U.S. patent for appetite suppression and obesity treatments that use its peptide drug-delivery technology. Release

> Israel's Oramed Pharmaceuticals has filed a patent application to develop an oral formulation combining two diabetes drugs currently available only in injectable form. Release

> Arcion Therapeutics has received a notice of allowance for a U.S. patent for its high strength, water-based gel formulation of topical lidocaine to treat post-herpetic neuralgia and shingles. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.